Document is current
Any future updates will be listed below
-
Authors
Heimann, Dominik
Kohnhäuser, Daniel
Kohnhäuser, Alexandra Jana
Brönstrup, Mark https://orcid.org/0000-0002-8971-7045
-
Funding
Funding for this research was provided by:
Deutsches Zentrum für Infektionsforschung (TTU09.712)
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
- License Information
-
More Information
Article History
Accepted: 2 December 2024
First Online: 23 January 2025
Declarations
:
: Alexandra Jana Kohnhäuser is employee of IPG DXTRA (Germany) GmbH, working for dna communications, but the work on this review was neither work-related, nor did she write about content connected to her work-related clients. Dominik Heimann, Daniel Kohnhäuser, Alexandra Jana Kohnhäuser and Mark Brönstrup have declared no conflicts of interest that may be relevant to the contents of this review.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Open Access funding enabled and organized by Projekt DEAL. Deutsches Zentrum für Infektionsforschung (TTU09.712).
: All authors: Design and concept of the entire manuscript. DH: Draft of the introduction, conclusion and chapters about DSTA4637S, zosurabalpin, murepavadin, voxvoganan, PL-18, PLG0206, OMN6 and anti-virulence therapeutics; creation of all figures and the global pipeline table. DK: Draft of chapters about DNA gyrase and topoisomerase IV inhibitors as well as β-lactamase inhibitors; creation of the global pipeline table. AJK: Draft of chapters about afabicin, TXA709, RG6436 and brilacidin. MB: Writing—review and editing, supervision.
